Revenues are expected to grow 30-33% in the fourth quarter of 2024 compared to the $6.1 million in revenues for the third quarter of 2024. Cash, cash equivalents, and available-for-sale securities as of December 31, 2024 were approximately $20.9 million, of which $11.4 million is subject to certain restrictions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Genomics announces publication on OGM for AML
- BioNano Genomics Announces $10 Million Direct Offering
- Bionano Genomics files to sell 50.56M share of common stock for holders
- Bionano sells 39.68M shares at 25.2c in registered direct offering
- BioNano Genomics Restructures Debt to Boost Liquidity